<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0">
<channel>
<title>Latest Biology Technology from Bio-Medicine.Org</title>
<link>http://www.bio-medicine.org/biology-technology-1/</link>
<description>Latest Biology Technology lists</description>
<language>en-us</language>
<copyright>Copyright 2007. Bio-Medicine All Rights Reserved.</copyright>
<item>
<title><![CDATA[Microbix Biosystems Re-files Annual Results With OSC]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Microbix-Biosystems-Re-files-Annual-Results-With-OSC-14756-1/</link>
<pubDate>Fri, 06 Nov 2009 04:07:58 MST</pubDate>
<description><![CDATA[TORONTO, Nov. 6 / Microbix Biosystems Inc. (the "Company") announces today that it has re-filed the Form 52-109F1 Certification of Annual Filings of William Gastle, the Chief Executive Officer and James Long, the Chief Financial Officer (the "Officer's Certificates") dated January 12, 2009 in connection with the annual audited financial statements for the year ended... ]]></description>
</item>
<item>
<title><![CDATA[Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Reissue-with-Tables-3A-BioSpecifics-Technologies-Corp--Reports-Third-Quarter-2009-Financial-Results-14755-1/</link>
<pubDate>Fri, 06 Nov 2009 01:28:36 MST</pubDate>
<description><![CDATA[LYNBROOK, N.Y., Nov. 6 /- BioSpecifics Technologies Corp. (Nasdaq:  BSTC ), a biopharmaceutical company developing first-in-class collagenase-based products, today announced its financial results for the third quarter ended September 30, 2009.        "We were extremely happy that, in September of this year, the FDA's Arthritis Advisory Committee unanimously recommend... ]]></description>
</item>
<item>
<title><![CDATA[Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Helix-BioPharma-to-Present-at-Merriman-Curhan-Fords-Investor-Summit-2009-on-November-10th-14754-1/</link>
<pubDate>Fri, 06 Nov 2009 01:28:27 MST</pubDate>
<description><![CDATA[AURORA, Ontario, Nov. 6 /- Helix BioPharma Corp. (TSX, FSE: "HBP" / Pink Sheets: HXBPF) today announced that John Docherty, president and chief operating officer, will present at Merriman Curhan Ford's 6th annual Investor Summit on November 10, 2009 at 4:00 PM at the Sofitel Hotel in New York City.  Mr. Docherty will provide an overview of the Company's leading produ... ]]></description>
</item>
<item>
<title><![CDATA[Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement &amp; Construction of World Scale Renewable Succinic Acid Plants]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Myriant-Technologies-LLC--Uhde-Corporation-of-America-and-Uhde-GmbH-Announce-Alliance-for-Engineering--Procurement--26amp-3B-Construction-of-World-Sca-14753-1/</link>
<pubDate>Fri, 06 Nov 2009 10:07:54 MST</pubDate>
<description><![CDATA[QUINCY, Mass., Nov. 6 /- Myriant Technologies LLC ("Myriant"), a privately-held, biotech developer and manufacturer of  renewable bio-chemicals, Uhde Corporation of America and its preferred technology provider Uhde GmbH, one of the world's leading engineering contractors (jointly "Uhde"), announced an alliance for the engineering, procurement &amp; construction (EPC) of Myria... ]]></description>
</item>
<item>
<title><![CDATA[EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/EUCODIS-Bioscience-to-Explore-Novel-Enzymatic-Activities-in-Antarctic-Bacteria-Library-From-Bio-Sidus-14752-1/</link>
<pubDate>Fri, 06 Nov 2009 08:18:49 MST</pubDate>
<description><![CDATA[VIENNA, Austria, November 6 /- EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry announced today that it has entered into a research agreement with Bio Sidus, the leading biopharmaceutical company in Latin America.            The agreement gives EUCODIS Bioscience exclusive access - for the search of enzym... ]]></description>
</item>
<item>
<title><![CDATA[NeurogesX Reports Third Quarter 2009 Results]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/NeurogesX-Reports-Third-Quarter-2009-Results-14751-1/</link>
<pubDate>Fri, 06 Nov 2009 08:18:42 MST</pubDate>
<description><![CDATA[SAN MATEO, Calif., Nov. 6 /-          3Q09 Corporate Highlights:          Completed transfer of Qutenza(TM) E.U. Marketing Authorization to Astellas Pharma Europe Ltd.   Made significant progress in commercial readiness activities  Expanded management team to include VP Sales; Senior Director, Marketing; and Director, Commercial Operations  Appointed Bradford S. Good... ]]></description>
</item>
<item>
<title><![CDATA[Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Calbiotech-Awarded-U-S--Army-Phase-I-SBIR-Research-Contract-to-Develop-Analyte-Specific-Reagents-for-the-Diagnosis-of-Dengue-Fever-Virus-14750-1/</link>
<pubDate>Fri, 06 Nov 2009 08:18:28 MST</pubDate>
<description><![CDATA[SPRING VALLEY, Calif., Nov. 6 /- Calbiotech, Inc. announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase I contract by the U.S. Army Medical Research and Material command. Under terms of the agreement, Calbiotech will develop analyte specific reagents (ASRs) for the diagnosis of Dengue virus.          Dengue virus is a mosquito-born flavivir... ]]></description>
</item>
<item>
<title><![CDATA[Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Oncolytics-Biotech-28R-29-Inc--Collaborators-Present-Positive-Phase-II-Sarcoma-Trial-Results-at-CTOS-Annual-Meeting-14749-1/</link>
<pubDate>Fri, 06 Nov 2009 08:18:23 MST</pubDate>
<description><![CDATA[CALGARY, Nov. 6 / Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th.... ]]></description>
</item>
<item>
<title><![CDATA[Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Intarcia-Therapeutics--Inc--Presents-Positive-Results-from-Two-Studies-of-ITCA-650-for-the-Treatment-of-Type-2-Diabetes-at-the-Ninth-Annual-Diabetes-T-14748-1/</link>
<pubDate>Fri, 06 Nov 2009 08:18:15 MST</pubDate>
<description><![CDATA[HAYWARD, Calif., Nov. 6 /- Intarcia Therapeutics, Inc. delivered two presentations today on its ITCA 650 (DUROS&#174; continuous delivery of exenatide) program for the treatment of type 2 diabetes at the Ninth Annual Diabetes Technology Meeting in San Francisco, CA:       (Logo:  http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO )         Continuous Subcutaneous Deliver... ]]></description>
</item>
<item>
<title><![CDATA[Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Leaders-in-Biopharma-and-Molecular-Diagnostics-to-Discuss-Key-Issues-and-Opportunities-in-Forming-Partnerships-at-2010-Personalized-Medicine-Partnersh-14747-1/</link>
<pubDate>Fri, 06 Nov 2009 01:53:13 MST</pubDate>
<description><![CDATA[The agenda for Arrowhead&rsquo;s 2010 Personalized Medicine Partnerships Conference, which is set to take place on February 22-24, 2010 in Philadelphia, has been announced. At this three day conference we will highlight key issues in forming partnerships and engage the best speakers to share their experiences.                            Minneapolis, MN (PRWEB) November... ]]></description>
</item>
<item>
<title><![CDATA[November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/November-2009-story-tips-from-the-US-Department-of-Energys-Oak-Ridge-National-Laboratory-14746-1/</link>
<pubDate>Thu, 05 Nov 2009 07:24:51 MST</pubDate>
<description><![CDATA[	 TRANSPORTATION -- Gone hybrid . . .     	 Fuel economy ratings for the new 2010 model year automobiles are now posted at the  www.fueleconomy.gov  web site, which Oak Ridge National Laboratory developed and maintains for the U.S. Department of Energy and the U.S. Environmental Protection Agency. Nine of the top 10 vehicles on the best fuel economy list are hybrid electrics, led by the Toyot... ]]></description>
</item>
<item>
<title><![CDATA[GenVec Reports Third Quarter 2009 Financial Results]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/GenVec-Reports-Third-Quarter-2009-Financial-Results-14745-1/</link>
<pubDate>Thu, 05 Nov 2009 04:20:17 MST</pubDate>
<description><![CDATA[GAITHERSBURG, Md., Nov. 5 /- GenVec, Inc. (Nasdaq:  GNVC ) today announced its financial results for the third quarter ended September 30, 2009. GenVec reported a net loss of $3.6 million ($0.04 per share) for the three months ended September 30, 2009 compared to a net loss of $6.8 million ($0.08 per share) in the comparable quarter of 2008. For the nine months ended... ]]></description>
</item>
<item>
<title><![CDATA[Colorado Companies Team Up With U.S. Fish &amp; Wildlife Service to Protect Black-Footed Ferret]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Colorado-Companies-Team-Up-With-U-S--Fish--26amp-3B-Wildlife-Service-to-Protect-Black-Footed-Ferret-14744-1/</link>
<pubDate>Thu, 05 Nov 2009 04:20:11 MST</pubDate>
<description><![CDATA[WELLINGTON, Colo., Nov. 5 /- The endangered black-footed ferrets inhabit prairie dog towns in the western U.S.  This rare carnivore feeds on prairie dogs.   The prairie dogs are very susceptible to plague and often entire population die-offs in towns occur.  The U.S. Fish &amp; Wildlife Service (FWS) has implemented a ferret breeding program and has been releasing trained, cap... ]]></description>
</item>
<item>
<title><![CDATA[DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/DSM-Pharmaceutical-Products-Forms-Manufacturing-Alliance-With-Galenix-14743-1/</link>
<pubDate>Thu, 05 Nov 2009 02:37:47 MST</pubDate>
<description><![CDATA[PARSIPPANY, N.J., Nov. 5 /- DSM Pharmaceutical Products today announced that it has made a manufacturing alliance with Galenix, Saint Jean D'Illac, France, where DSM will be the preferred commercial scale manufacturing partner for Galenix commercial products on a global basis.       DSM and Galenix will collaborate on business development opportunities co-marketing Galenix dru... ]]></description>
</item>
<item>
<title><![CDATA[Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Imagenetix-to-Present-at-2nd-Annual-LD-MICRO-Conference-at-the-Luxe-Sunset-Bel-Air-14742-1/</link>
<pubDate>Thu, 05 Nov 2009 02:37:42 MST</pubDate>
<description><![CDATA[SAN DIEGO, Nov. 5 /- Imagenetix, Inc. (OTC Bulletin Board: IAGX), announced today that William Spencer, President and CEO of Imagenetix, will be presenting the Company's story at the 2nd annual LD MICRO Conference on Thursday, December 3rd, at 10:30 AM PST at the Luxe Sunset in Los Angeles.       About LD MICRO       LD MICRO is a by-invitation only newsletter firm t... ]]></description>
</item>
<item>
<title><![CDATA[ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/ThermoGenesis-Reports-15-Percent-Increase-in-First-Quarter-Revenues-3B-Improved-Bottom-Line-14741-1/</link>
<pubDate>Thu, 05 Nov 2009 02:37:38 MST</pubDate>
<description><![CDATA[RANCHO CORDOVA, Calif., Nov. 5 /- ThermoGenesis Corp. (Nasdaq:  KOOL ), a leading supplier of innovative products for processing and storing adult stem cells, today reported results for the first quarter of fiscal 2010.       For the quarter ended September 30, 2009, the Company reported revenues of $5.2 million, a 15 percent increase over revenues of $4.5 million in... ]]></description>
</item>
<item>
<title><![CDATA[OncoGenex Reports Third Quarter 2009 Financial Results]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/OncoGenex-Reports-Third-Quarter-2009-Financial-Results-14740-1/</link>
<pubDate>Thu, 05 Nov 2009 02:37:31 MST</pubDate>
<description><![CDATA[Conference Call on Thursday, November 5, 2009 at 4:30 p.m. Eastern Time        BOTHELL, WA and VANCOUVER Nov. 5 / OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ:  OGXI ) today reported unaudited financial results for the third quarter and nine months ended September 30, 2009 and reviewed the Company's highlights for the third quarter of 2009.... ]]></description>
</item>
<item>
<title><![CDATA[Transgenomic, Inc. Reports Third Quarter 2009 Results]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Transgenomic--Inc--Reports-Third-Quarter-2009-Results-14739-1/</link>
<pubDate>Thu, 05 Nov 2009 02:37:22 MST</pubDate>
<description><![CDATA[OMAHA, Neb., Nov. 5 /- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today announced financial results for the quarter ended September 30, 2009. The Company's financial results are presented in the tables that follow.        Third Quarter 2009        The Company reported a net loss of $366,000 or $0.01 per share for the third quarter of 2009 as compared to a net loss... ]]></description>
</item>
<item>
<title><![CDATA[BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/BioSpecifics-Technologies-Corp--Reports-Third-Quarter-2009-Financial-Results-14738-1/</link>
<pubDate>Thu, 05 Nov 2009 02:37:12 MST</pubDate>
<description><![CDATA[LYNBROOK, N.Y., Nov. 5 /- BioSpecifics Technologies Corp. (Nasdaq:  BSTC ), a biopharmaceutical company developing first-in-class collagenase-based products, today announced its financial results for the third quarter ended September 30, 2009.        "We were extremely happy that, in September of this year, the FDA's Arthritis Advisory Committee unanimously recommend... ]]></description>
</item>
<item>
<title><![CDATA[Cepheid to Webcast Upcoming Financial Presentations]]></title>
<link>http://www.bio-medicine.org/biology-technology-1/Cepheid-to-Webcast-Upcoming-Financial-Presentations-14737-1/</link>
<pubDate>Thu, 05 Nov 2009 02:37:07 MST</pubDate>
<description><![CDATA[SUNNYVALE, Calif., Nov. 5 /- Cepheid (Nasdaq:  CPHD ) today announced that its executives will be speaking at the following investor conferences, and invited investors to participate via webcast.                     Credit Suisse Healthcare Conference, Phoenix, AZ                  Thursday, 12 November, 2009 at 10 a.m. Mountain Time                   NASDAQ OMX 23rd... ]]></description>
</item>
</channel>
</rss>